| 9.99 0.1 (1.01%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.98  |
1-year : | 16.32 |
| Resists | First : | 11.97 |
Second : | 13.98 |
| Pivot price | 9.47 |
|||
| Supports | First : | 9.41 |
Second : | 7.84 |
| MAs | MA(5) : | 9.92  |
MA(20) : | 9.22 |
| MA(100) : | 7.96 |
MA(250) : | 7.6 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 44 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 11.97 | Low : | 5.01 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NVAX ] has closed below upper band by 31.5%. Bollinger Bands are 61.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.05 - 10.1 | 10.1 - 10.14 |
| Low: | 9.41 - 9.46 | 9.46 - 9.51 |
| Close: | 9.9 - 9.99 | 9.99 - 10.07 |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Wed, 04 Mar 2026
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Tue, 03 Mar 2026
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Tue, 03 Mar 2026
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Tue, 03 Mar 2026
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
Sat, 28 Feb 2026
Novavax, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Fri, 27 Feb 2026
Why Novavax (NVAX) Shares Are Falling Today - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 69.6 (%) |
| Shares Short | 51,180 (K) |
| Shares Short P.Month | 54,720 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.96 |
| Profit Margin | 32 % |
| Operating Margin | -112.7 % |
| Return on Assets (ttm) | 18 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -16.7 % |
| Gross Profit (p.s.) | 3.89 |
| Sales Per Share | 6.52 |
| EBITDA (p.s.) | 2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -378 (M) |
| Levered Free Cash Flow | -455 (M) |
| PE Ratio | 4.97 |
| PEG Ratio | 0 |
| Price to Book value | -10.41 |
| Price to Sales | 1.53 |
| Price to Cash Flow | -4.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|